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The coumarins or vitamin K antagonists, have been the mainstay of oral anticoagulant
therapy for more than 60 years. Their effectiveness has been established by well-designed
clinical trials for both the primary and secondary prevention of venous thromboembolism,
for the prevention of systemic embolism in patients with prosthetic heart valves or atrial
ﬁbrillation, as an adjunct in the prophylaxis of systemic embolism after myocardial infarc-
tion, and for reducing the risk of recurrent myocardial infarction. Oral anticoagulants
(OAC) are challenging to use in clinical practice for the following reasons:
• they have a narrow therapeutic window;
• they exhibit considerable variability in dose response among patients due to genetic and
other factors;
• they are subject to interactions with drugs and diet;
• their laboratory control is difﬁcult to standardize;
• maintenance of a therapeutic level of anticoagulation requires a good understanding of
the pharmacokinetics;
• pharmacodynamics of OAC plus good patient communication.
Indications for oral anticoagulation have increased in recent years. OAC require fre-
quent monitoring for the international normalized ratio (INR) and prothrombin time (PT)
to keep the intensity within the therapeutic range and to minimize the risk for bleeding
complications. Approaches to improve anticoagulant control include the use of anticoagu-
lation clinics to manage therapy, point-of-care (POC) of INR testing and computer software
programs to aid dose adjustment.
 Comparison of INR stability between self-monitoring and standard laboratory method: Preliminary results of a prospective study in 67
mechanical heart valve patients, Dauphin C., Legault B., Jaffeux P., Motreff P., Azarnoush K., Aublet-Cuvelier B., Camilleri L., Lusson J.R.,
Cassagnes J., de Riberolles C., doi:10.1016/j.acvd.2008.10.007.
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POC monitors measure a thromboplastin-mediated clot-
ing time from a ﬁngerstick sample of capillary whole blood.
he results are then converted to a plasma-PT equivalent
y a microprocessor and are expressed as a PT or INR. Each
anufacturer typically establishes a conversion formula by
imultaneously comparing ﬁngerstick results with an estab-
ished laboratory method. Good agreement between the
lasma reference laboratory method and new generation
evices have been demonstrated (0.86 to 0.98). Further-
ore, within-day precision for normal or abnormal control
lasma have been reported with a coefﬁcient of variation
anging from 3.5 to 5%. Some limitations do exist, however,
uch as the tendency to underestimate elevated INR and
he inadequacy of the method in cases of anaemia, fever or
nﬂammatory syndrome. Furthermore, some devices may be
nﬂuenced by heparin residues.
A recent consensus statement for the anticoagulation
orum underlined that long-term use of OAC can be opti-
ized by a systematic evidence-based approach to therapy
ncluding patient education, selection and supervision.
atients’ self-control and self-management have been found
o improve signiﬁcantly the quality of OAC treatment [1].
Two recent meta-analyses [2,3] highlighted the fact that
elf-management of OAC improves the quality of oral anti-
oagulation. Patients capable of self-monitoring and/or
elf-adjusting therapy have fewer thrombolytic events and
ower mortality. Self-monitoring is not feasible for all
atients, however, and requires the identiﬁcation and edu-
ation of suitable candidates.
Guidelines from the American College of Chest Physician
4] recommend that physicians, who manage oral antico-
gulation therapy do so in a systematic and coordinated
ashion, incorporating patient education, systematic INR
esting, tracking, follow-up, and good patient communica-
ion of results and dose adjustments (Grade 1B). In patients
ho are suitably selected and trained, patient self-testing or
atient self-management of dosing are effective alternative
reatment models that result in improved quality of antico-
gulation management, with greater time in the therapeutic
ange and fewer adverse events. Patient self-monitoring or
elf-management, however, is a choice made by patients and
hysicians that depends on many factors. We suggest that
uch therapeutic management can be implemented where
uitable (Grade 2B).
Such POC devices are currently commercially available in
umerous countries in Europe and America. These devices
lso became available and are reimbursed in France in June
f this year, but only for children who need long-term anti-
oagulant therapy.
The present study presented by Dauphin et al. [5] reports
he preliminary results of a single-centre, open, random-
zed study that compared monthly laboratory monitoring
group A) with weekly self-monitoring (group B) of INR in
atients undergoing single or multiple mechanical valve
eplacements either alone or in combination with coro-
ary revascularization. The primary aim of the study was to
mprove INR stability within the target range; the secondary
[R. Roudaut
im was to reduce the number of adverse events. At the
tart of the study, the aim was to enroll 100 patients divided
qually into two groups. The authors reported the results of
he intermediate analysis on the ﬁrst 67 patients enrolled.
his is the ﬁrst study to evaluate INR self-monitoring in
rance. It shows that this method yields better stability of
he INR within the target range, and decreases the number
f serious haemorrhages (11.8% in group A versus 0% in group
).
The 4A study ‘‘Apport d’un Appareil d’Automesure de
’Anticoagulation’’ is currently being conducted in France
n a population of patients recently ﬁtted with a mechan-
cal heart valve. It is a nationwide, multicentre (24 sites),
andomized, blinded trial with two study groups:
conventional follow-up of anticoagulation: at least
monthly checks and adjustment of the INR by the family
doctor (n = 350 patients);
self-measurement of anticoagulation by patients at home,
and weekly measurement and adjustment of the INR by
the family doctor (n = 700 patients).
The main objective is to evaluate the economic impact
f a self-measurement strategy. The secondary objectives
re the impact on complications (bleeding, thromboembolic
vents and death), the proportion of monthly INR values
ithin the target range, the evaluation of patients’ learning
bout the procedure, and patients’ compliance and satis-
action with the procedure. Inclusion into the study began
n May 2007, with each patient participating for 12 months.
he ﬁnal results will become available in 2010.
Finally, self-monitoring of glycaemia in diabetic patients
s both essential and indispensable nowadays. Undoubt-
dly, self-monitoring of OAC allows the INR to be checked
ore frequently, always using the same machine (which is
orrelated with an improvement in anticoagulation). Fur-
hermore, this method allows patients to manage their
reatment better, which in turn leads to improved compli-
nce with therapy. We think that POC devices for INR control
ill in the future improve signiﬁcantly the safety of long-
erm OAC therapy.
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